The convergence of life sciences and technology has created tremendous opportunities to accelerate innovation in the industry. This acceleration was further fueled by the COVID-19 pandemic, where the race to develop new therapies and vaccines to treat COVID-19 resulted in an unprecedented number of transactions between and among companies of all shapes and sizes, including competitors.
This roundtable discussion, led by Matt Karlyn and Mai Zymaris of Morrison & Foerster’s Boston Life Sciences Group, will focus on best practices and considerations for any company entering into a collaboration or licensing deal. Topics include:
Disclaimer
Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.